These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26947314)

  • 1. Combination Therapy of Denosumab and Calcitriol for a Renal Transplant Recipient with Severe Bone Loss due to Therapy-Resistant Hyperparathyroidism.
    Wada Y; Iyoda M; Iseri K; Arai-Nunota N; Saito T; Hamada T; Tachibana S; Ikeda M; Shibata T
    Tohoku J Exp Med; 2016 Mar; 238(3):205-12. PubMed ID: 26947314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Rare Reason for Severe Hypocalcemia Following Kidney Transplant: Denosumab Treatment.
    Aktas M; Oray Unlu HN; Karatas M; Okut G; Eren B; Uslu A; Tatar E
    Exp Clin Transplant; 2024 Jan; 22(Suppl 1):342-344. PubMed ID: 38385423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.
    Asano T; Shimizu T; Takahashi D; Ota M; Sato D; Hamano H; Hiratsuka S; Takahata M; Iwasaki N
    J Bone Miner Metab; 2019 Mar; 37(2):351-357. PubMed ID: 29721807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis.
    Ebina K; Kashii M; Hirao M; Hashimoto J; Noguchi T; Koizumi K; Kitaguchi K; Matsuoka H; Iwahashi T; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2017 Sep; 35(5):571-580. PubMed ID: 27830384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab-Induced Hypocalcemia and Hyperparathyroidism in de novo Kidney Transplant Recipients.
    Cianciolo G; Tondolo F; Barbuto S; Iacovella F; Zavatta G; Altieri P; Grandinetti V; Comai G; Cozzolino M; La Manna G
    Am J Nephrol; 2021; 52(8):611-619. PubMed ID: 34518468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
    Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
    J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting.
    Simonini M; Bologna A; Vezzoli G
    Int Urol Nephrol; 2024 Oct; 56(10):3285-3293. PubMed ID: 38856936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
    Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
    BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
    Dave V; Chiang CY; Booth J; Mount PF
    Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea.
    Cha S; Sohn M; Yang H; Yeh EJ; Baek KH; Ha J; Ku H
    BMC Musculoskelet Disord; 2024 Jan; 25(1):76. PubMed ID: 38245776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
    Yasuda Y; Iwama S; Arima H
    Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.